Compare Twilio Inc (TWLO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twilio Inc vs Viatris Inc — how do they compare? Twilio Inc trades at $290.42 (market cap $42.35B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Twilio Inc is far larger — about 2.1× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Twilio Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twilio Inc for 56 Days and Viatris Inc for 57 Days on average.
| TWLO | VTRS | |
|---|---|---|
Market Cap | $42.35B | $20.03B |
Volume | 1,862,642 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $301.27 | $18.27 |
52-Week Low | $106.23 | $9.74 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | $40.76B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twilio (TWLO) trades at $289.18, up 5.93% in the past 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company's revenue growth accelerated to $5.07 billion in 2025, with net income turning positive at $33.83 million, and is projected to reach $1.1 billion in 2026. Recent inclusion in the S&P 500 index and positive analyst sentiment with 76.92% buy ratings highlight investor confidence, though high valuation multiples like a P/E of 38.09 and EV/EBITDA of 81.63 suggest premium pricing.
The outlook for Twilio is positive, driven by robust revenue growth, expanding profitability, and strategic positioning in AI-driven communications. Key risks include elevated valuation metrics that may limit upside, competitive pressures, and potential volatility from market reactions to earnings. Institutional interest remains strong, but investors should weigh growth prospects against current premium valuations.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
